By Patrick McGee 
 

Two jumbo-size bond deals are bringing some life back to the corporate-debt market after a couple of quiet sessions.

Watson Pharmaceuticals Inc. (WPI) has a prescription for a $3.9 billion, three-part bond deal, and insurance holding company MetLife Inc. (MET) is issuing a $1 billion, two-part offering.

Both companies aim to take advantage of rock-bottom borrowing costs. Average yields declined to 2.81% Wednesday, setting a record for the second time this week, according to a Barclays index dating back to 1973.

Watson is raising funds for its $5.94 billion acquisition of Swiss rival Actavis Group. The pharmaceutical sector has seen a series of acquisitions lately, many of them related to major drug makers' efforts to build up their pipelines as many pharmaceutical product patents are set to expire in coming years.

The Actavis deal, announced in April, would more than double Watson's international access and make it the world's third-largest maker of generic drugs, according to The Wall Street Journal.

The bonds are rated Baa3--the lowest investment-grade rating--by Moody's Investors Service, and BBB by Standard & Poor's Ratings Services and Fitch Ratings.

Moody's on Thursday said the Actavis acquisition would raise Watson's financial leverage to roughly four times equity, versus 1.2 times at the end of the second quarter. It also said the acquisition would "significantly boost Watson's global competitive position."

Watson is offering senior unsecured notes with maturities of five, 10 and 30 years. They are anticipated to offer 1.35, 1.70 and 1.90 percentage points of yield more than comparable Treasury rates, according to a term sheet.

When Watson last issued five- and 10-year notes in August 2009, it paid spreads to Treasurys of 2.625 percentage points on each.

MetLife, which boasts A3 and A-minus ratings from Moody's and S&P, is selling $1 billion of bonds evenly divided between five- and 10-year maturities. They are expected to offer 1.05 and 1.35 percentage points over Treasurys. The offer yields fell 0.05 point from earlier pricing guidance, reflecting strong demand.

The two deals will push the month's issuance to $114.7 billion, according to Dealogic. That makes September the second-busiest month this year, after March, and the eighth-busiest month in 17 years of records.

-Tess Stynes contributed to this article.

Write to Patrick McGee at patrick.mcgee@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Watson (NYSE:WPI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Watson Charts.
Watson (NYSE:WPI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Watson Charts.